- Home
- CSTL vs EQV Comparison
CSTL vs EQV Comparison
Compare CSTL & EQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- EQV
- Stock Information
- Founded
- CSTL 2007
- EQV 2024
- Country
- CSTL United States
- EQV United States
- Employees
- CSTL N/A
- EQV N/A
- Industry
- CSTL Medical Specialities
- EQV
- Sector
- CSTL Health Care
- EQV
- Exchange
- CSTL Nasdaq
- EQV Nasdaq
- Market Cap
- CSTL 456.2M
- EQV 472.5M
- IPO Year
- CSTL 2019
- EQV 2024
- Fundamental
- Price
- CSTL $18.52
- EQV $10.62
- Analyst Decision
- CSTL Strong Buy
- EQV
- Analyst Count
- CSTL 6
- EQV 0
- Target Price
- CSTL $37.67
- EQV N/A
- AVG Volume (30 Days)
- CSTL 419.5K
- EQV 209.9K
- Earning Date
- CSTL 08-04-2025
- EQV 01-01-0001
- Dividend Yield
- CSTL N/A
- EQV N/A
- EPS Growth
- CSTL N/A
- EQV N/A
- EPS
- CSTL N/A
- EQV N/A
- Revenue
- CSTL $347,083,000.00
- EQV N/A
- Revenue This Year
- CSTL N/A
- EQV N/A
- Revenue Next Year
- CSTL $1.36
- EQV N/A
- P/E Ratio
- CSTL N/A
- EQV $51.68
- Revenue Growth
- CSTL 38.43
- EQV N/A
- 52 Week Low
- CSTL $15.45
- EQV $9.88
- 52 Week High
- CSTL $35.84
- EQV $10.74
- Technical
- Relative Strength Index (RSI)
- CSTL 56.09
- EQV N/A
- Support Level
- CSTL $17.89
- EQV N/A
- Resistance Level
- CSTL $19.38
- EQV N/A
- Average True Range (ATR)
- CSTL 0.82
- EQV 0.00
- MACD
- CSTL 0.26
- EQV 0.00
- Stochastic Oscillator
- CSTL 77.46
- EQV 0.00
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About EQV EQV Ventures Acquisition Corp.
EQV Ventures Acquisition Corp is a blank check company.